The American Society of Clinical Oncology 2023 annual meeting kicked off Friday in Chicago, and BioSpace’s Greg Slabodkin spoke with leading biopharma analysts about the most-anticipated ASCO abstracts.
Keep checking back for more ASCO highlights.
June 2.: Novartis presented early data from a Phase III trial of Kisqali (ribociclib) in HR-positive HER2-negative early-stage breast cancer. The addition of Kisqali in the adjuvant setting reduced patients’ risk for recurrence by 25% compared to those on the endocrine therapy alone.
June 2
In March, BioNTech dropped $200 million upfront for exclusive global rights to OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392. On Friday, the development partners reported positive early data to be presented at ASCO from a Phase I/II trial studying the drug—now BNT316/ONC-392—in metastatic, PD-(L)1-resistant non-small cell lung cancer (NSCLC).
Data from 27 patients showed an overall response rate of 29.6% and a disease control rate of 70.4%. One patient had a complete response, seven saw a partial response and 11 patients had stable disease. BioNTech and OncoC4 called the safety profile “manageable” with Grade 3 or 4 Immune-related adverse events occurring in 10 patients.
“Responses were observed regardless of PD-L1 status, and among those who failed multiple lines of immunotherapy and chemotherapy, including PD-1 and CTLA-4 combination therapy,” Pan Zheng, chief medical officer and co-founder at OncoC4, said in a prepared statement.
A pivotal Phase III trial is expected to begin in the third quarter of 2023, according to the press release.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.